Literature DB >> 10072628

Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.

T Sejima1, I Miyagawa.   

Abstract

OBJECTIVES: This study was designed to examine the immunohistochemical expression of bcl-2, p53, and proliferating cell nuclear antigen (PCNA) and the relation of this expression to clinicopathological characteristics and prognosis in renal cell carcinoma (RCC).
METHODS: The expression of bcl-2, p53 protein, and PCNA was studied by immunohistochemical methods in paraffin-embedded nephrectomy specimens from 53 patients whose clinicopathological data had already become clear.
RESULTS: The expression of the bcl-2 protein was recognized in 34 cases (64%); the expression of the p53 protein, however, was seen in only 1 case. Bcl-2 positivity was not associated with any pathological parameters or prognosis. If the percentage of PCNA-positive cancer cells as compared to the total amount of cancer cells was defined as a labeling index (LI), a high PCNA LI number correlated significantly with a high T category, high grade, venous invasion, and shortened survival. Among the conventional pathological parameters, the T category, nuclear grade, and venous invasion had the most significant effect on prognosis. A multivariate analysis in the parameters of PCNA, T category, nuclear grade, and venous invasion demonstrated that only nuclear grade had a significant effect on prognosis.
CONCLUSIONS: The inhibitory effect of the bcl-2 gene on apoptosis related to tumor development is not clear, and the expression of the p53 protein is uncommon in RCC. PCNA seems to be a good objective and quantitative marker of the biological malignant potential in RCC, although the assessment of malignant potential in combination with conventional pathological parameters is indispensable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072628     DOI: 10.1159/000019855

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Study of apoptosis in human liver cancers.

Authors:  Chang-Min Shan; Juan Li
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  The relationship of expression of bcl-2, p53, and proliferating cell nuclear antigen (PCNA) to cell proliferation and apoptosis in renal cell carcinoma.

Authors:  Zhaohui Zhu; Shian Xing; Ping Cheng; Guosheng Li; Yu Yang; Fuqing Zeng; Gongcheng Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 3.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 4.  Clear cell adenocarcinoma of the colon: a case report and review of literature.

Authors:  Koichi Soga; Hideyuki Konishi; Natsuko Tatsumi; Chika Konishi; Keimei Nakano; Naoki Wakabayashi; Shoji Mitsufuji; Keisho Kataoka; Takeshi Okanoue; Ken-Ichi Mukaisho; Takanori Hattori
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

5.  Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma.

Authors:  Ambrosi Pertia; David Nikoleishvili; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-08-05       Impact factor: 2.370

6.  Characterisation of the progression of azaserine-induced rat pancreatic adenocarcinoma by proliferative cell nuclear antigen, basement membrane laminin and trypsinogen immunohistochemistry.

Authors:  Krisztina Nagy; Zsolt Pálfia; Gábor Réz
Journal:  Histochem Cell Biol       Date:  2003-05-13       Impact factor: 4.304

7.  Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.

Authors:  Jinhee Kim; Eric Jonasch; Angela Alexander; John D Short; Shengli Cai; Sijin Wen; Dimitra Tsavachidou; Pheroze Tamboli; Bogdan A Czerniak; Kim Anh Do; Kevin J Wu; Laura A Marlow; Christopher G Wood; John A Copland; Cheryl Lyn Walker
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

8.  Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Jyue-Yu Chen; Wang-Yi Kang; Ying-Chu Lin; Yu-Shiang Shiu; Shu-Ju Chuang; Hong-Jeng Yu; Ming-Kuen Lai; Yu-Chieh Tsai; Wen-Jeng Wu; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2012-04-05       Impact factor: 8.410

9.  Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations.

Authors:  Vassilis Samaras; Maria Tsopanomichalou; Angeliki Stamatelli; Christos Arnaoutoglou; Efstathios Samaras; Marianthi Arnaoutoglou; Hercules Poulias; Calypso Barbatis
Journal:  Diagn Pathol       Date:  2009-02-17       Impact factor: 2.644

10.  Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients.

Authors:  T Itoi; K Yamana; V Bilim; K Takahashi; F Tomita
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.